These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 9734549

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Depression in premenopausal women: gonadal hormones and serotonergic system assessed by D-fenfluramine challenge test.
    Rajewska J, Rybakowski JK.
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Jun; 27(4):705-9. PubMed ID: 12787860
    [Abstract] [Full Text] [Related]

  • 23. Prolactin response to D-fenfluramine in outpatients with major depression.
    Kavoussi RJ, Kramer J, Hauger RL, Coccaro EF.
    Psychiatry Res; 1998 Jul 13; 79(3):199-205. PubMed ID: 9704866
    [Abstract] [Full Text] [Related]

  • 24. Hormonal responses to fenfluramine in depressed and control subjects.
    Mitchell P, Smythe G.
    J Affect Disord; 1990 May 13; 19(1):43-51. PubMed ID: 2140846
    [Abstract] [Full Text] [Related]

  • 25. Hormonal responses to fenfluramine in depressive subtypes.
    Mitchell P, Smythe G, Parker G, Wilhelm K, Hickie I, Brodaty H, Boyce P.
    Br J Psychiatry; 1990 Oct 13; 157():551-7. PubMed ID: 2131137
    [Abstract] [Full Text] [Related]

  • 26. Cortisol and prolactin responses to d-fenfluramine in non-depressed patients with obsessive-compulsive disorder: a comparison with depressed and healthy controls.
    Lucey JV, O'Keane V, Butcher G, Clare AW, Dinan TG.
    Br J Psychiatry; 1992 Oct 13; 161():517-21. PubMed ID: 1393339
    [Abstract] [Full Text] [Related]

  • 27. Gender differences in a fenfluramine-activated FDG PET study of borderline personality disorder.
    Soloff PH, Meltzer CC, Becker C, Greer PJ, Constantine D.
    Psychiatry Res; 2005 Apr 30; 138(3):183-95. PubMed ID: 15854787
    [Abstract] [Full Text] [Related]

  • 28. Modulation of cortical neuronal activity by a serotonergic agent: a PET study in humans.
    Kapur S, Meyer J, Wilson AA, Houle S, Brown GM.
    Brain Res; 1994 May 23; 646(2):292-4. PubMed ID: 8069675
    [Abstract] [Full Text] [Related]

  • 29. Risk and resilience markers in bipolar disorder: brain responses to emotional challenge in bipolar patients and their healthy siblings.
    Krüger S, Alda M, Young LT, Goldapple K, Parikh S, Mayberg HS.
    Am J Psychiatry; 2006 Feb 23; 163(2):257-64. PubMed ID: 16449479
    [Abstract] [Full Text] [Related]

  • 30. Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm.
    Meyer JH, McMain S, Kennedy SH, Korman L, Brown GM, DaSilva JN, Wilson AA, Blak T, Eynan-Harvey R, Goulding VS, Houle S, Links P.
    Am J Psychiatry; 2003 Jan 23; 160(1):90-9. PubMed ID: 12505806
    [Abstract] [Full Text] [Related]

  • 31. A fenfluramine-activated FDG-PET study of borderline personality disorder.
    Soloff PH, Meltzer CC, Greer PJ, Constantine D, Kelly TM.
    Biol Psychiatry; 2000 Mar 15; 47(6):540-7. PubMed ID: 10715360
    [Abstract] [Full Text] [Related]

  • 32. Assessment of serotonergic function in major depression using d-fenfluramine: relation to clinical variables and antidepressant response.
    Cleare AJ, Murray RM, O'Keane V.
    Biol Psychiatry; 1998 Oct 01; 44(7):555-61. PubMed ID: 9787879
    [Abstract] [Full Text] [Related]

  • 33. Acute challenge with d-fenfluramine decreases regional cerebral glucose utilization in Sham, but not in OBX, rats: an autoradiographic study.
    Skelin I, Sato H, Diksic M.
    Brain Res; 2010 Jan 15; 1310():162-71. PubMed ID: 19912994
    [Abstract] [Full Text] [Related]

  • 34. Cholesterol and serotonin indices in depressed and suicidal patients.
    Sarchiapone M, Camardese G, Roy A, Della Casa S, Satta MA, Gonzalez B, Berman J, De Risio S.
    J Affect Disord; 2001 Feb 15; 62(3):217-9. PubMed ID: 11223109
    [Abstract] [Full Text] [Related]

  • 35. Nutrient imbalances in depressive disorders. Possible brain mechanisms.
    Wurtman RJ, O'Rourke D, Wurtman JJ.
    Ann N Y Acad Sci; 1989 Feb 15; 575():75-82; discussion 82-5. PubMed ID: 2699207
    [Abstract] [Full Text] [Related]

  • 36. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders.
    Meltzer CC, Price JC, Mathis CA, Greer PJ, Cantwell MN, Houck PR, Mulsant BH, Ben-Eliezer D, Lopresti B, DeKosky ST, Reynolds CF.
    Am J Psychiatry; 1999 Dec 15; 156(12):1871-8. PubMed ID: 10588399
    [Abstract] [Full Text] [Related]

  • 37. Reduced serotonin responsivity in depression.
    Brown GM.
    Am J Psychiatry; 1997 Mar 15; 154(3):442. PubMed ID: 9054808
    [No Abstract] [Full Text] [Related]

  • 38. Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls.
    Neumeister A, Nugent AC, Waldeck T, Geraci M, Schwarz M, Bonne O, Bain EE, Luckenbaugh DA, Herscovitch P, Charney DS, Drevets WC.
    Arch Gen Psychiatry; 2004 Aug 15; 61(8):765-73. PubMed ID: 15289275
    [Abstract] [Full Text] [Related]

  • 39. Blunted serotonergic responsivity in depressed inpatients.
    Mann JJ, McBride PA, Malone KM, DeMeo M, Keilp J.
    Neuropsychopharmacology; 1995 Aug 15; 13(1):53-64. PubMed ID: 8526971
    [Abstract] [Full Text] [Related]

  • 40. Central serotonin activity and aggression: inverse relationship with prolactin response to d-fenfluramine, but not CSF 5-HIAA concentration, in human subjects.
    Coccaro EF, Kavoussi RJ, Cooper TB, Hauger RL.
    Am J Psychiatry; 1997 Oct 15; 154(10):1430-5. PubMed ID: 9326827
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.